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Methods: Two randomized, placebo-controlled, double-blind studies were performed using single and
multiple ascending JNJ-54861911 doses (up to 14 days) in young and elderly healthy participants. Reg-
ular blood samples and frequent CSF samples, up to 36 hours after last dose, were collected to assess
the pharmacokinetic and pharmacodynamic (Ab, sAPPa,b,total levels) profiles of JNJ-54861911.
Results: JNJ-54861911 was well-tolerated, adverse events were uncommon and unrelated to JNJ-
54861911. JNJ-54861911 showed dose-proportional CSF and plasma pharmacokinetic profiles.
Plasma- and CSF-Ab and CSF-sAPPb were reduced in a dose-dependent manner. Ab reductions
(up to 95%) outlasted exposure to JNJ-54861911. APOE ε4 carrier status and baseline Ab levels
did not influence Ab/sAPPb reductions.
Conclusion: JNJ-54861911, a potent brain-penetrant BACE1 inhibitor, achieved high and stable Ab
reductions after single and multiple dosing in healthy participants.
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Alzheimer’s disease (AD) is a neurodegenerative disorder
characterized by progressive memory loss and cognitive
decline. The neuropathologic hallmarks of AD are extracel-
lular plaques of insoluble amyloid b (Ab), intracellular neu-
rofibillary tangles (NFT) composed of hyperphosphorylated
tau protein and atrophy of the cerebral cortex [1]. All these
pathologic changes begin years before the onset of
symptoms [2].
Multiple lines of evidence support the amyloid cascade
hypothesis stating that Ab accumulation and deposition
are the initiating factors for the pathogenesis of AD [3,4].
The hypothesis puts forward factors such as increased
production or decreased clearance of Ab from the central
nervous system (CNS), driving the Ab accumulation in
brain. As a consequence, agents preventing formation of
Ab could have disease-modifying properties for AD. Ab is
generated from the amyloid precursor protein (APP). The
amyloidogenic processing of APP is initiated by b-site
APP cleaving enzyme 1 (BACE1). BACE1 is an aspartyl
protease, cloned initially by several groups [5,6], that
cleaves the N-terminus of Ab, followed by g-secretase
cleaving the C-terminal end. In this process, BACE1
cleavage is the first and rate-limiting step. Subsequent g-sec-
retase cleavage results in formation of Ab species of
different lengths, from which Ab1–40 is the predominant
one. The cleavage site for another APP processing enzyme,
a-secretase, lies within the Ab sequence and thus precludes
Ab formation. The relationship of physiological a-secretase
to b-secretase processing is not fully understood, and
BACE1 inhibition studies suggest that APP can be shifted
to other pathways [7]. The amino terminal fragment gener-
ated through a-secretase or b-secretase cleavage is called
soluble APP (sAPP) a or b, respectively.
Inhibitors of BACE1 prevent the formation of Ab and
would therefore be potential therapeutic agents for AD.
BACE1 has emerged over the past decade as the drug
target of choice for reducing central Ab levels in AD.
Several BACE inhibitors are currently in clinical develop-
ment for different stages of AD [8–13]. JNJ-54861911 is
the first BACE inhibitor being developed by Janssen in
collaboration with Shionogi. Herein, we describe the safety
and tolerability, and peripheral and central pharmacokinetic
(PK) and pharmacodynamic (PD) characteristics of JNJ-
54861911 after single and multiple dosing. Confirmation
of peripheral and central BACE1 inhibition, and as such
target engagement of JNJ-54861911, was assessed primarily
by Ab1–40 levels in plasma and cerebrospinal fluid (CSF).2. Methods
2.1. Clinical studies
Two randomized, placebo-controlled, double-blind,
single-site clinical studies were performed using single-(SAD) and multiple-ascending dose (MAD) administrations
in young healthy men and elderly healthy men and women.
Both study protocols and amendments were reviewed by
an Investigational Review Board (Commissie voor Medi-
sche Ethiek, Ziekenhuis Netwerk Antwerpen (ZNA), Ant-
werp, Belgium). All procedures followed were in
accordance with the principles of the Declaration of Hel-
sinki. Written informed consent was obtained from all par-
ticipants before participation. The studies are registered on
ClinicalTrials.gov: NCT01827982 and NCT01887535.
2.2. Study population
Young men (18–54 years; body mass index [BMI], 18 to
30 kg/m2) and elderly men or women (55–75 years; BMI, 18
to 32 kg/m2) considered healthy based on medical history,
physical examination, 12-lead ECGs, and clinical laboratory
evaluations (see Supplemental data for key inclusion
criteria) were enrolled in the SAD and MAD studies from
April 2013 to December 2013 at SGS, Life Science Services,
Clinical Pharmacology Unit, Belgium.
2.3. Clinical study designs and treatments
In the SAD study, young participants (N 5 8) received a
single dose of 1-mg JNJ-54861911 (N 5 6) or placebo
(N 5 2). Elderly participants (N 5 48) received escalating
single dose levels as oral suspension of 1, 3, 10, 30, 90, or
150 mg of JNJ-54861911 (N 5 6/cohort) or placebo
(N 5 2/cohort).
In theMAD study, elderly participants (N5 38) received,
double blind, JNJ-54861911 (N 5 6/cohort), or placebo
(N 5 2/cohort) as oral suspension at escalating doses of 5,
30, 50, or 90-mg QD or open label as solid dose formulation
of 25-mg QD (N 5 6) for 14 days. A single young healthy
men cohort to explore safety and tolerability at higher
dose level received 150-mg JNJ-54861911 (N 5 6) or pla-
cebo (N5 2) as solid-dose formulation for 7 days. An addi-
tional enlarged cohort of elderly participants to assess
potential QTc liabilities received JNJ-54861911 (N 5 18)
or placebo (N 5 6) as oral suspension for 7 days (See
Supplemental data for a detailed description).
2.4. Safety assessments
Safety was assessed before and after dosing by recording
adverse events (AE), physical and neurological examina-
tions, vital signs, 12-lead ECGs, 24-hour Holter monitoring,
and clinical laboratory tests. All participants were included
in the safety analysis.
2.5. PK and PD assessments
Plasma and urine concentrations of JNJ-54861911 and
PD effects in plasma were evaluated at regular time points
(limited PD assessments were applied in the QT cohort;
see Supplemental data).
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PK and PD effects of JNJ-54861911 were assessed in
CSF on day 1 (SAD; 6 mL/sample) and day 14 (MAD;
4 mL/sample) using serial CSF sampling through an
indwelling subarachnoid lumbar catheter from 2 hours
before until 36 hours after the last dosing, as described
previously [14].
In addition, in theMAD study, a baseline CSF samplewas
collected by single lumbar puncture (LP) predose on day
1 (12 mL).
From all participants, a pharmacogenomic sample was
collected and APOE ε4 carrier status was analyzed [15].2.6. Bioanalytical methods2.6.1. Analysis of JNJ-54861911
Plasma, urine, and CSF JNJ-54861911 samples were
analyzed using a scientific validated [16], specific, and sen-
sitive liquid chromatographic–mass spectrometry/mass
spectrometry method (see Supplemental data). The lower
limit of quantification (LLOQ) was 1 ng/mL.
2.6.2. Analysis of plasma and CSFAb concentrations
A qualified prototype multiplex immunoassay based on
Meso Scale Discovery (MSD; Gaithersburg, MD) electro-
chemiluminescence detection (ECL) technology was used
for simultaneous detection of 4 Ab species (Ab1–37, Ab1–
38, Ab1–40, and Ab1–42) [17,18]. Plasma samples were
analyzed after pretreatment with Heterophilic Blocking
Reagent-9 (HBR-9, Scantibodies, Laboratory, Inc., CA).
As in plasma most of the concentrations of Ab1–37,
Ab1–38, and Ab1–42 were near or lower than LLOQ, only
Ab1–40 concentrations are reported.
2.6.3. Analysis of CSF sAPP concentrations
sAPPa, sAPPb, and sAPP total were quantified in CSF
using MSD ECL detection technology. For the MAD study,
day 1 and day 14 predose samples together with samples
taken at day 14 at 10, 24, and 36 hours after dose were
analyzed. sAPPa and sAPPb CSF concentrations were
measured using MSD 96-well MULTI-SPOT sAPPa/sAPPb
assay according to manufacturer’s instructions [19].
For sAPP total, an MSD ECL assay developed by Janssen
Research &Development was used (see Supplemental data).
Both Ab and sAPP were determined using a standard
curve with 4-parameter logistic model with 1/Y2 weighting
function. All samples from each participant were analyzed
in duplicate on the same assay plate. Only mean values
with replicate well coefficient of variation (CV) of 20%
were accepted.
2.6.4. Analysis of baseline CSFAb1–42, P-tau181P, and T-tau
levels
Baseline Ab1–42, phosphorylated tau at position threonine
181 (P-tau181P) and total tau (T-tau) concentrations weremeasured using INNO-BIA AlzBio3 kit reagents and Lumi-
nex analytical platform [20,21].2.7. Statistical analysis2.7.1. Sample size
For mean % change in CSF Ab1–40, a dose group of six
participants and a pooled placebo group of 10 participants
was expected to provide a 1-sided 90% confidence interval
for between treatment difference with a precision of 69,
based on a SD of 12 observed earlier [14].3. Results
3.1. Demographic characteristics
All participants completed the studies, except one in the
MAD study, who withdrew consent on day 28. Eight elderly
participants in the SAD and four elderly participants in the
MAD study had Ab1–42 concentrations below the threshold
(249 pg/mL), suggestive of cerebral amyloid plaque deposi-
tion [21], but none had elevated T-tau or P-tau181P values
(data not shown). Overall, 28.6% (n 5 16/56) and 27.1%
(n 5 19/70) of all participants enrolled in the SAD and
MAD study respectively were identified as APOE ε4 car-
riers. Across both studies, a total of 94 participants, mainly
Caucasian, received one or more doses of JNJ-54861911
(Table S1).
In the SAD study, 8 young men (1 mg; mean age,
44.8 years) and 48 elderly men and women (1–150 mg;
mean age, 64.2 years) participated in the study.
In the MAD study, 62 elderly men and women (5–90 mg;
mean age, 64.8 years) and 8 young men (150 mg; mean age,
39.6 years) were enrolled. Within studies, the average mea-
sures for age, height, BMI, Ab1–42, P-tau181P, and T-tau at
baseline were comparable among treatments for the elderly
participants enrolled in cohorts measuring CSF in the SAD
(P 5 not significant [NS] for all, F test) and MAD
(P 5 NS for all) study. Gender and APOE ε4 status were
comparable among treatments (P 5 NS, Fisher exact test)
in the SAD study, whereas there was a slight imbalance of
these parameters in the MAD study (both P 5 .08, Fisher’s
exact test; Table S1).3.2. Safety and tolerability
Single and multiple oral doses of JNJ-54861911 ranging
between 1 and 150 mg were well-tolerated. AEs were un-
common, occurred with similar frequency in the placebo
and JNJ-54861911 treatment groups, and are probably
attributable to the LP procedure (Table S2).
In participants receiving JNJ-54861911, the most com-
mon AEs (10 participants) were headache (SAD, 16/42
[38.1%] vs placebo, 7/14 [50%]; MAD, 13/52 [25.0%]
vs placebo, 1/18 [5.6%]) and back pain (SAD, 10/42
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placebo, 2/18 [11.1%]). All other AEs were observed in
8 participants receiving either a single or multiple
dose of JNJ-54861911 or placebo. There were no apparent
trends in AEs with regard to dose.
There were no serious AEs (SAEs) or significant changes
noted in vital signs, physical, and neurological measure-
ments, or ECG (12-lead ECG; Holter monitoring), nor
were there any investigator-identified laboratory AEs or
clinically relevant laboratory abnormalities.3.3. Pharmacokinetic properties of JNJ-54861911
Anoverview of the plasma andCSFPKparameters and pro-
files is provided as Supplementary Material (Supplementary
Table S3–S6 and Supplementary, Figs. S1 and S2). After single
and multiple doses, plasma JNJ-54861911 Cmax and AUC
increased dose-proportionally from 1 to 150 mg and appeared
similar between healthy young and elderly participants. JNJ-
54861911 plasma PK profiles were characterized by rapid ab-
sorption (median Tmax of 0.75–2 hours following single dose,
and 2–4 hours after multiple dosing) and essentially biphasic
decline at all dose levels (Supplementary Figs. S1). After mul-
tiple dosing, mean T1/2 on day 14 ranged from 14.4 to
18.5 hours compared to 9.0 to 16.1 hours after single dose.
Steady state JNJ-54861911 concentrations following multiple
dosing were reached by day 5 for all cohorts, which is consis-
tent with the observed T1/2. Mean accumulation ratios for
steady-state Cmax and AUCt on day 14 ranged from 1.27 to
1.73 ng/mL and 1.34 to 2.17 ng h/mL, respectively.Mean renal
clearance values of JNJ-54861911 between day 1 (single dose;
data not shown) and day 14 (Supplementary Table S5) were
similar (0.111 vs 0.115 L/h) and comparable across studies.
JNJ-54861911 levels in CSF were assayed only in
elderly participants (Supplementary Tables S4 and S6).
Single-dose CSF concentrations of JNJ-54861911 were
generally below the LOQ for the 1-mg and 3-mg dose
level. After single and multiple doses, both Cmax
and AUC in CSF increased dose proportionally across
doses studied (10–150 mg). Maximal mean concentra-
tions in CSF (2.94–22.7 ng/mL) on day 1 were reached
between 2.0 and 3.0 hours. After multiple dosing, me-
dian Tmax in CSF on day 14 was approximately 4 hours
and mean T1/2 ranged from 11.7 to 14.4 hours across
doses studied. Plasma and CSF Tmax after single and
multiple dose were similar. Dose-normalized plasma
and CSF PK were comparable between formulations
used (Supplementary Tables S4 and S5). Finally, CSF
PK profiles appeared to be parallel to corresponding
plasma PK profiles at each dose group (Supplementary
Figs. S1 and S2). CSF concentrations were approxi-
mately 3% of total plasma concentrations, and 50%–
60% of free plasma concentrations, estimated based on
a plasma-free fraction of 6%.3.4. Pharmacodynamics of JNJ-548619113.4.1. Plasma and CSFAb
To investigate target engagement, CSF and plasma Ab
levels were monitored over time.
In the SAD study, dose-dependent reduction of plasma and
CSF Ab1–40 concentrations versus baseline was observed
(Fig. 1 and Supplementary Fig. S3). The reduction in plasma
(Fig. 1A and Supplementary Fig. S3A) was characterized by a
fast onset with strongest reduction during the first 4 hours af-
ter dose, approaching (close to) maximal effects in all doses.
In young healthy men (1-mg dose), a similar plasma Ab pro-
file was seen as in elderly healthy participants (data not
shown). Higher doses (10, 30, 90, and 150 mg) achieved
70% to 80%Ab reduction at 4 hours after dose, and the reduc-
tion compared to baseline was long lasting. Analysis of later
time points showed a slow return to baseline concentrations
for all dose groups, with reductions remaining up till 96 hours
after dose for all groups from 3–150 mg.
Compared to plasma, reduction of CSFAb1–40 concentra-
tions showed a later onset and slower kinetics (Fig. 1B and
Supplementary Fig. S3B). As anticipated based on earlier
findings reported by Van Broeck et al. 2015 [14], the high-
frequency CSF collection scheme resulted in an initial
mean increase of Ab1–40 levels over baseline. Over the first
6 hours, no apparent treatment effect was observed. After
6 hours, a dose-dependent reduction of Ab1–40 levels started.
Although doses of 1 and 3 mg trended slightly below placebo,
no relevant Ab1–40 reduction could be observed. Increasing
doses yielded a dose-dependent reduction of Ab1–40 concen-
trations. The maximum observed reduction after single
dosing was 75% (36 hours after 150 mg). The Ab-lowering
effect was persistent over 36 hours for the highest doses (90
and 150 mg), whereas participants treated with lower doses
showed a trend for return to baseline 36 hours after dose.
In the MAD study, reduction of plasma and CSF Ab1–40
levels from baseline was stable until at least 24 hours after
last dose in participants receiving a once daily dose of
JNJ-54861911 for 14 days (Fig. 2). Plasma reductions
were dose dependent with participants dosed with 5 mg
JNJ-54861911 having reductions of 60%–75%, at 30 mg
75%–85%, at 50 mg around 90%, and at 90-mg 90%–95%
(Fig. 2A). The reductions in the 25-mg tablet group were
close to those in the 30-mg oral suspension group. Similar
to the SAD study, no notable changes from baseline were
observed in participants receiving placebo. Analysis of
time points beyond 36 hours showed a slow return to base-
line concentrations, with reductions remaining up till
72 hours after dose for all treatment groups.
Similarly in CSF, a dose-dependent decrease in Ab1–40
levels was observed compared to baseline (Fig. 2B). The
Ab1–40 reduction in plasma was numerically stronger
compared to CSF at the lowest dose of 5 mg. In contrast to
the SAD study, no marked increase above baseline was
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Fig. 1. Dose-dependent plasma (A) and CSF (B) Ab1–40 reduction with mean dose normalized plasma and CSF JNJ-54861911 concentrations in the SAD study.
Ab data are represented as mean percent change from baseline over time. 1-mg cohort was only analyzed till 24 hours after treatment. CSF analysis of 3-mg
cohort was performed till 28 hours after dose (data 36 hours were rejected). Plasma and CSF JNJ-54861911 concentrations presented as mean dose normalized
profiles, obtained by dose-normalizing all individual PK profiles and averaging them at each time point.
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Fig. 2. Stable and dose-dependent plasma (A) and CSF (B) Ab1–40 reduction in the MAD study as measured 14–15 days after repeated dosing with JNJ-
54861911. Data of day 14 are represented as mean percent change from baseline (day 1) over time (including 95% CI bars [CI, confidence interval]). Plasma
samples were taken during a longer period (up to 72 hours) as compared to CSF (up to 36 hours).
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dependent Ab1–40 reductions were seen: 50% at 5 mg/day,
80% to 85% at 30 mg; about 90% at 50 mg; and 90% to
95% at 90 mg. The reductions after treatment with the 25-
mg tablet were similar to those with 30-mg oral suspension.
Similar to the observed reductions in plasma, all reductions
in CSF were stable up till 24 hours after the last dose on day
14, not only on a group mean level, but also at an individual
level (data not shown). Thirty-six hours after the last dose,
there was a trend toward normalization for the lowest dose
of 5 mg, whereas reductions remained relatively stable for
the higher dose groups.
For all cohorts, CSF concentrations of all measured Ab
species (Ab1–37, Ab1–38, Ab1–40, and Ab1–42) demonstrated
similar changes in Ab levels versus baseline (Fig. 3).
3.4.2. Pharmacodynamics of CSF sAPP
To obtain direct evidence of specific BACE1 inhibition in
the CNS, sAPPa, sAPPb, and sAPP total were measured in a
selection of CSF samples of the MAD study (Fig. 4).
sAPPb concentrations decreased in a dose-dependent and
stable manner after 14 days dosing comparable to Ab1–40.
sAPPa increased to a similar extent in 30-, 50-, and 90-mg
cohorts, not exceeding a 2-to-2.5-fold increase versus base-
line levels (Fig. 4). sAPP total levels remained rather con-
stant over the full observation period.Fig. 3. Stable reduction in Ab species (Ab1–42, Ab1–40, Ab1–38, Ab1–37) in CSF com
JNJ-54861911. Data of day 14 are represented as mean percent change from basel
presented are representative for all other cohorts. Number of participants for whom
below figure.Additionally, APOE ε4 carrier status and baseline Ab
levels (data not shown) did not impact the mean of the
maximum percent Ab or sAPPb reduction from baseline
(Fig. 5).
3.4.3. PK/PD relationship in plasma and CSF
Comparison between PK and PD parameters in plasma
and CSF revealed clear differences. In plasma, the onset of
Ab lowering is parallel to the PK profile, with maximum
Ab reduction close to Tmax (Fig. 1A). In CSF, Ab lowering
was delayed compared to CSF PK, with Ab reduction start-
ing only 6 hours after dose (Fig. 1B).4. Discussion
Preclinical studies in transgenic animal models have
demonstrated a link between BACE1 inhibition and
lowering of Ab levels in the brain, as well as prevention or
even reversal of amyloid deposition [22–24]. These
findings, together with results from genetic studies [25], un-
derscored the potential of BACE1 inhibitor treatment in AD,
and currently several compounds are in various stages of
clinical development [13].
We describe the results of first-in-human studies in which
the safety and tolerability, PK and PD of a novel BACE1pared to baseline as measured 14–15 days after repeated dosing with 90-mg
ine (day 1) over time (including 95% CI bars). Data of the 90-mg dose level
samples could be analyzed and for which levels were above LOQ is indicated
Fig. 4. CSF sAPPa increase and sAPPb decrease in the MAD study as measured 14–15 days after repeated dosing with JNJ-54861911. Data are represented as
mean of the average percent change from baseline (day 1) over 24 hours, 14–15 days after repeated dosing (6 standard deviation). Total sAPP levels remained
rather constant over the observation period. CSF Ab1–40 reduction is included to allow comparison with measured changes in sAPP species.
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pants after single and multiple doses.
In general, JNJ-54861911 was well tolerated in both
studies. Overall AEs observed and reported were uncom-
mon, occurred with similar frequency in placebo and
JNJ-54861911 treatment groups and were probably attrib-Fig. 5. APOE ε4 carrier status has no impact on Ab or sAPPb reduction. Data are r
14 (24 hours).utable to the LP procedures. AE profiles related to the
LP procedures were comparable to previously reported
LP-related AEs [14]. There were no apparent trends in
AEs reported with regard to dose. No significant differ-
ences in AE profiles were observed between tablet and
oral suspension formulation.epresented as mean of maximum percent change from day 1 baseline on day
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tween young and elderly, across studies and between for-
mulations (suspension vs. tablet). JNJ-54861911 exhibited
rapid absorption and multiphasic decline across dose
levels. The extent of absorption was similar between pop-
ulations and studies. Dose linearity was observed across
all treatment groups after single and multiple dosing in
CSF and plasma (Cmax and AUCt), with doses ranging
from 1 to 150 mg.
In the MAD study, steady state plasma levels were
reached by day 5. The sustained PD effects outlasted the
PK profile, making this drug suitable for once daily dosing.
The decrease in mean plasma Ab1–40 levels was dose
dependent. In the SAD study, onset of Ab1–40 reduction
was fast and parallel to PK. Even at 96 hours after dosing,
reduction in plasma Ab1–40 levels was still present for
most dose groups, whereas compound concentrations were
low or even below quantification limit at that time point.
The reason for these long-lasting effects on plasma Ab1–40
is currently unknown but might be related to intracellular
compartmentalization of the compound [11]. The fact that
reductions in plasma Ab can be long lasting has been
observed in other studies in healthy participants as well
[8,11]. In the MAD study, a stable 90%–95% inhibition of
plasma Ab1–40 was noted in the 90-mg dose group after
14 days of dosing. Mean percent change in Ab1–40 levels
from baseline was stable up to at least 24 hours in all dose
groups.
Analysis of CSFAb1–40 levels revealed no apparent treat-
ment effect over the first 6 hours after a single dose of JNJ-
54861911. After 6 hours, a dose-dependent decrease in CSF
Ab1–40 levels was observed which continued in the 150-mg
group until the end of the observation period at 36 hours,
whereas lower doses trended toward normalization earlier.
The initially observed increase in CSF Ab1–40 levels versus
predose levels was most probably related to the high fre-
quency and/or volume of CSF sampling [14]. Indeed, in
the MAD study, where a lower sampling frequency scheme
and volume was applied, Ab1–40 levels in the placebo group
did not show significant changes compared to predose sam-
ples. Here, a dose-dependent and stable reduction in CSF
Ab1–40 levels was observed allowing for a QD dosing
regimen. Studies with other BACE inhibitors described
various extents of dose-dependent CSF Ab reductions in
healthy participants [8,10,26]. In contrast to the
observations in plasma, CSF Ab1–40 reductions showed a
delay compared to the PK profile of JNJ-54861911. The
rate of onset of CSF Ab lowering was similar to production
rate of new Ab in CSF of healthy participants [27]. It is plau-
sible that plasma and CSF Ab reductions are driven by pe-
ripheral and central activity, respectively. Additionally,
baseline Ab or APOE ε4 genotype had no relevant impact
on Ab reduction.
In accordance with the mechanism of action of BACE1
inhibitors, it was also confirmed that Ab species of various
lengths were reduced in parallel. Moreover, sAPPb levelswere shown to exhibit dose-dependent reduction, providing
direct evidence of b-secretase inhibition in the human
CNS. In agreement with earlier studies, sAPPb and Ab
decreased in a similar manner [10]. The concomitant in-
crease in sAPPa indicated increased processing through
the a-secretase pathway, as has been demonstrated before
in CSF [26,28–31].5. Conclusions
JNJ-54861911 is a potent, brain-penetrant BACE1 inhib-
itor, achieving robust and high (up to 95%) CSF Ab reduc-
tion with once daily oral dosing in healthy elderly
participants, in absence of significant AEs. Ab reduction
outlasted plasma/CSF pharmacokinetics, leading to sus-
tained PD activity. These results support JNJ-54861911 as
a promising candidate to test in patient populations for its
potential to mitigate AD disease progression and thus clini-
cally validate the amyloid cascade hypothesis.Acknowledgments
The authors are most grateful to the study participants for
their contributions and the investigational staff for the med-
ical care. The authors acknowledge Kouji Ohno (Research
Laboratory for Development, Shionogi & Co., LTD., Osaka,
Japan) and Yoshiyuki Matsuo (Global Project Management
Dept., Shionogi & Co., LTD., Osaka, Japan) for data review
and discussions. The authors acknowledge Ashwini Patil,
MS, ISMPP CMPP (SIRO Clinpharm Pvt. Ltd.) for medical
writing assistance (funded by Janssen Research and Devel-
opment, LLC), and Bradford Challis, PhD (Janssen
Research & Development, LLC), for additional editorial
support. The authors also thank Marianne Borgers, Luc
Gys and Daan Van Glabbeek for their contributions to the
development of sAPP assays and QPS Netherlands B.V.
for CSF and plasma Ab analyses.
This research was funded by Janssen Research & Develop-
ment, a division of Janssen Pharmaceutica N.V., Beerse,
Belgium and by a Transformational Medical Research Grant
(IWT 120834) from Flanders Innovation & Entrepreneur-
ship (VLAIO), Belgium.
Author contributions: J.R.S., L.V.N., L.T., and M.T. de-
signed the study; J.R.S., B.V.B., M.M., J.S., E.L., V.S.,
A.R., H.S., L.V.N., L.T., K.D.W., and M.T. were responsible
for data collection and analysis. J.B. was the project statisti-
cian. S.R. was the principal investigator for this study and
was responsible for study execution. All authors participated
in interpretation of the data and drafting of the manuscript.
All authors met ICMJE criteria and all those who fulfilled
those criteria are listed as authors. All authors had access
to the study data, provided direction and comments on the
manuscript, made the final decision about where to publish
these data, and approved the final draft and submission to
this journal.
M. Timmers et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 202-212 211Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.trci.2016.08.001.RESEARCH IN CONTEXT
1. Systematic review: BACE-1 is an emerging target for
potential treatment of Alzheimer’s disease (AD). We
describe the results of first-in-human phase-1 studies
of a novel BACE1 inhibitor, JNJ-54861911, in which
the safety and tolerability, pharmacokinetics and
pharmacodynamics were evaluated in healthy par-
ticipants after single and multiple-doses.
2. Interpretation: JNJ-54861911 achieved robust and
high (up to 95%) CSFAb reduction with once daily
oral dosing in healthy elderly participants, and was
well tolerated in both studies. Ab reduction out-
lasted plasma/CSF pharmacokinetics, leading to
sustained pharmacodynamic activity. Our results
support the existing hypothesis that BACE-1 inhi-
bition may be of therapeutic benefit in reducing Ab
levels in AD.
3. Future directions: These results support JNJ-
54861911 as a promising candidate to test in target
patient populations for its potential to mitigate AD
disease progression and thus clinically validate the
amyloid cascade hypothesis.References
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